Efficacy of intravitreal Aflibercept in patients with neovascular AMD who were previously treated with Ranibizumab based on a Treat and Extend protocol

被引：0
|
作者：
Turksever, C.
Prunte, C.
Hatz, K.
机构：
来源：
ACTA OPHTHALMOLOGICA | 2015年 / 93卷
关键词：
D O I：
10.1111/j.1755-3768.2015.0396
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
ABS15-0396
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Conversion to aflibercept for patients with neovascular age-related macular degeneration who were refractory to ranibizumab treatment
    Kawashima, Yu
    Oishi, Akio
    Miyake, Masahiro
    Yoshikawa, Munemitsu
    Takahashi, Ayako
    Ueda, Naoko
    Tamura, Hiroshi
    Yamashiro, Kenji
    Tsujikawa, Akitaka
    Yoshimura, Nagahisa
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [22] Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
    Razavi, Sam
    Kodjikian, Laurent
    Giocanti-Auregan, Audrey
    Dufour, Ingrid
    Souied, Eric
    BMC OPHTHALMOLOGY, 2021, 21 (01)
  • [23] Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
    Sam Razavi
    Laurent Kodjikian
    Audrey Giocanti-Aurégan
    Ingrid Dufour
    Eric Souied
    BMC Ophthalmology, 21
  • [24] Comparison of Ranibizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration treated following a 'Treat and Extend' protocol: efficacy variables from the pre-specified 12-month interim analysis of the RIVAL study
    Gillies, Mark C.
    Hunyor, Alex
    Arnold, Jennifer
    Pecheur, Francois
    Underhill, Kathryn
    Guymer, Robyn H.
    McAllister, Ian
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [25] COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED FOLLOWING A 'TREAT AND EXTEND' PROTOCOL: EFFICACY VARIABLES FROM THE PRE-SPECIFIED 12-MONTH INTERIM ANALYSIS OF THE RIVAL STUDY
    Gillies, Mark C.
    Hunyor, Alex P.
    Arnold, Jennifer J.
    Pecheur, Francois
    Underhill, Kathryn
    Guymer, Robyn H.
    McAllister, Ian L.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 45 : 29 - 29
  • [26] Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration
    Aki Kato
    Tsutomu Yasukawa
    Iichiro Sugita
    Munenori Yoshida
    Miho Nozaki
    Yoshio Hirano
    Junko Kondo
    Tomohiro Abe
    Kimiko Sugita
    Takahide Okita
    Hiroshi Morita
    Noriaki Takase
    Yuichiro Ogura
    Advances in Therapy, 2022, 39 : 1403 - 1416
  • [27] Mental Status and Feasibility of an Intravitreal Ranibizumab Treat-and-Extend Regimen in Patients with Neovascular Age-Related Macular Degeneration
    Kato, Aki
    Yasukawa, Tsutomu
    Sugita, Iichiro
    Yoshida, Munenori
    Nozaki, Miho
    Hirano, Yoshio
    Kondo, Junko
    Abe, Tomohiro
    Sugita, Kimiko
    Okita, Takahide
    Morita, Hiroshi
    Takase, Noriaki
    Ogura, Yuichiro
    ADVANCES IN THERAPY, 2022, 39 (03) : 1403 - 1416
  • [28] Ganglion cell complex changes in wet AMD patients treated with anti-VEGF intravitreal injections according to a treat-and-extend protocol
    Cao, Jessica
    Mongy, Mohamed
    Ferreira, Lisia
    Brent, Michael Henry
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2024, 59 (02): : 96 - 101
  • [29] Efficacy of Intravitreal Aflibercept Treat-and-Extend Regimen Over 2 Years for Neovascular Age-Related Macular Degeneration: ARIES Study
    Souied, Eric H.
    Holz, Frank G.
    Hykin, Philip G.
    Midena, Edoardo
    Wolf, Sebastian
    Allmeier, Helmut
    Mitchell, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [30] Retrospective analysis of patients with neovascular Age-related Macular Degeneration (nAMD) switched from ranibizumab to aflibercept and switched back to ranibizumab, using a treat and extend regimen
    Rumen, Franck
    Uzzan, Joel
    Oubraham, Hassiba
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
12345